Achondroplasia is a genetic skeletal disorder and the most common form of short-limbed dwarfism, characterized by impaired conversion of cartilage to bone, especially in long bones. It is associated with FGFR3 variants and typical features such as disproportionate short stature and macrocephaly.
BioMarin reported first-quarter 2026 revenue of $766 million and raised full-year guidance to $3.825 billion-$3.925 billion. The company highlighted FDA approval of PALYNZIQ for adolescents and upcoming Phase 3 readouts for BMN 401 and VOXZOGO.
BridgeBio shares rose 2.10% to $69.41 after Phase 3 FORTIFY interim data for oral BBP-418 in LGMD2I/R9 showed broad efficacy and placebo-matched safety. The company plans a U.S. FDA filing in H1 2026.
The FDA has cleared Abbisko Therapeutics' IND application for ABSK061, an oral FGFR2/3 inhibitor for achondroplasia, while BridgeBio reports positive Phase 3 results for its oral infigratinib in the same condition. Both companies are advancing oral therapies targeting FGFR3 overactivity in this genetic growth disorder.
The FDA approved navepegritide, a once-weekly injectable therapy for achondroplasia, while phase 3 data showed infigratinib, an investigational oral medication, achieved the highest growth velocity reported in randomized trials for the condition.
The FDA has granted accelerated approval for YUVIWEL (navepegritide), the first once-weekly treatment for children with achondroplasia. Commercial availability is expected in early Q2 2026, with a Rare Pediatric Disease Priority Review Voucher granted.
BridgeBio Pharma announced positive Phase 3 topline results for infigratinib in children with achondroplasia, meeting primary and key secondary endpoints. The company plans regulatory submissions in the U.S. and Europe in the second half of 2026.
BridgeBio Pharma reported positive Phase 3 results for oral infigratinib in children with achondroplasia, meeting primary and secondary endpoints with superior growth velocity and the first statistically significant improvement in body proportionality. The company plans regulatory submissions in the second half of 2026.
BridgeBio Pharma announced positive Phase 3 topline results for infigratinib in children with achondroplasia, meeting primary and key secondary endpoints. The company plans regulatory submissions in the U.S. and Europe in the second half of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07441876 |
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia |
RECRUITING | PHASE2/PHASE3 |
| NCT07388966 |
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia |
RECRUITING | |
| NCT07301463 |
A Study in Children With Achondroplasia |
RECRUITING | |
| NCT07297875 |
A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07169279 |
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) |
RECRUITING | PHASE2 |
| NCT06926491 |
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） |
RECRUITING | PHASE3 |
| NCT06842355 |
A Study of TYRA-300 in Children With Achondroplasia: BEACH301 |
RECRUITING | PHASE2 |
| NCT06732895 |
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. |
RECRUITING | PHASE2 |
| NCT06433557 |
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06168201 |
VIrtual STudy in Achondroplasia for the US (VISTA) |
RECRUITING |
